# US 2004/0001837 A1 · Betulinol derivatives

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0001837 A1
- Document ID: US20040001837A1
- Status: Published application
- Kind: A1
- Application number: 09/089,894
- Filed: 1998-06-03
- Published: 2004-01-01
- Earliest claimed: 1997-06-04
- Assignees: Cornell Research Foundation, Inc.
- Inventors: ARKADIY L. BOMSHTEYN; PREMILA RATHNAM; BRIJ B. SAXENA
- Web page: https://patentgrep.com/patent/US20040001837A1

## CPC

- C07J 53/00: Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, {including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class}
- C07J 1/00: Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J: STEROIDS (seco-steroids C07C)

## Abstract

The present invention is directed to betulinol derivatives and betulinol-antibody conjugates having the formulae: 1 and HO-antibody-spacer-(A2)n wherein A1 is a moiety having the formula: 2 A2 is a moiety having the formula: 3 n is an integer from 1 to 100; X and Y1 are each independently selected from the group consisting of a hydroxy group, an alkoxy group, an alkanoyloxy group, and a-peptide-NHNH—C(O)-antibody-OH moiety; Y2 is selected from the group consisting of a hydroxy group, an alkoxy group, and an alkanoyloxy group; and HO-antibody-H is an antibody and, in particular, betulinol dimethyl ether. Methods for making and using these derivatives and conjugates, as well as a method for making and using betulonic aldehyde, are also disclosed.

## Claims

### Claim 1

A diether having the formula:
42
wherein R is an alkyl group.

### Claim 2 (depends on 1)

A diether according to claim 1, wherein R is methyl.

### Claim 3

A method of synthesizing a diether having the formula:
43
wherein R is alkyl,
said method comprising:
providing a dialcohol having the formula:
44
and
alkylating the dialcohol with a nitrile having the formula:
R—C≡N
under conditions effective to form the diether.

### Claim 4 (depends on 3)

A method according to claim 3, wherein R is methyl.

### Claim 5 (depends on 3)

A method according to claim 3, wherein the dialcohol and the nitrile, respectively, are present in a mole ratio of from about 1:20 to about 1:60.

### Claim 6 (depends on 3)

A method according to claim 3, wherein said alkylating is carried out at a temperature of from about 30° C. to about 70° C.

### Claim 7

A method of preparing betulonic aldehyde comprising:
oxidizing betulinol with chromium anhydride in acetone in the presence of sulfuric acid under conditions effective to produce betulonic aldehyde.

### Claim 8 (depends on 7)

A method according to claim 7, wherein the betulinol and acetone, respectively, are present in a weight ratio of from about 1:100 to about 1:100.

### Claim 9 (depends on 7)

A method according to claim 7, wherein the chromium anhydride and sulfuric acid, respectively, are present in a molar ratio of from 9:10 to about 10:9.

### Claim 10 (depends on 7)

A method according to claim 7 further comprising, after said oxidizing:
cooling the reaction mixture; and
adding water to the reaction mixture, whereby a sediment containing betulonic aldehyde forms.

### Claim 11 (depends on 10)

A method according to claim 10 further comprising:
recrystallizing the sediment.

### Claim 12

A compound having the formula:
45
wherein
X or Y is a -peptide-Q moiety and the other of X and Y is a hydroxy group, an alkoxy group, an alkanoyloxy group, or a -peptide-Q moiety;
Q is a hydroxy group, a —NHNH2 moiety, an —NHNH—C(O)CH2Hal moiety, an -antibody-OH moiety, or an —NHNH—C(O)-antibody-OH moiety; and
Hal is a halogen.

### Claim 13 (depends on 12)

A compound according to claim 12, wherein -peptide-is a pentapeptide.

### Claim 14 (depends on 13)

A compound according to claim 13, wherein the pentapeptide is -Gly-Ala-Leu-Gly-Leu-.

### Claim 15 (depends on 12)

A compound according to claim 12, wherein -peptide-is a tetrapeptide.

### Claim 16 (depends on 15)

A compound according to claim 15, wherein the tetrapeptide is -Leu-Ala-Leu-Ala-.

### Claim 17

A method of producing a betulinol-antibody conjugate having the formula:
46
wherein
Y is a hydroxy group, an alkoxy group, or an alkanoyloxy group,
said method comprising:
providing a betulinol peptide having the formula:
47
and
converting the betulinol peptide with an antibody having the formula H-antibody-OH under conditions effective to produce the betulinol-antibody conjugate.

### Claim 18 (depends on 17)

A method according to claim 17, wherein -peptide-is a pentapeptide.

### Claim 19 (depends on 18)

A method according to claim 18, wherein the pentapeptide is -Gly-Ala-Leu-Gly-Leu-.

### Claim 20 (depends on 17)

A method according to claim 17, wherein -peptide-is a tetrapeptide.

### Claim 21 (depends on 20)

A method according to claim 20, wherein the tetrapeptide is -Leu-Ala-Leu-Ala-.

### Claim 22 (depends on 17)

A method according to claim 17, wherein said providing the betulinol peptide comprises:
providing a compound having the formula:
48
and
converting the compound with a peptide having the formula H-peptide-OH under conditions effective to produce the betulinol peptide.

### Claim 23

A method of producing a betulinol-antibody conjugate having the formula:
49
wherein
Y is a hydroxy group, an alkoxy group, or an alkanoyloxy group,
said method comprising:
providing a haloacetylhydrazide having the formula:
50
wherein
Hal is a halogen
and
converting the haloacetylhydrazide with an antibody having the formula H-antibody-OH under conditions effective to produce the betulinol-antibody conjugate.

### Claim 24 (depends on 23)

A method according to claim 23, wherein Hal is I.

### Claim 25 (depends on 23)

A method according to claim 23, wherein -peptide-is a pentapeptide.

### Claim 26 (depends on 25)

A method according to claim 25, wherein the pentapeptide is -Gly-Ala-Leu-Gly-Leu-.

### Claim 27 (depends on 23)

A method according to claim 23, wherein -peptide-is a tetrapeptide.

### Claim 28 (depends on 27)

A method according to claim 27, wherein the tetrapeptide is -Leu-Ala-Leu-Ala-.

### Claim 29 (depends on 23)

A method according to claim 23, wherein said providing a haloacetylhydrazide comprises:
providing a hydrazide having the formula:
51
and
converting the hydrazide with a p-nitrophenyl haloacetate under conditions effective to produce the haloacetylhydrazide.

### Claim 30 (depends on 29)

A method according to claim 29, wherein said providing a hydrazide comprises:
providing a betulinol peptide having the formula:
52
and
converting the betulinol peptide with hydrazine hydrate under conditions effective to produce the hydrazide.

### Claim 31 (depends on 30)

A method according to claim 30, wherein said providing the betulinol peptide comprises:
providing a compound having the formula:
53
and
converting the compound with a peptide having the formula H-peptide-OH under conditions effective to produce the betulinol peptide.

### Claim 32

A betulinol-antibody conjugate having the formula:
54
wherein
A are independently selected from a —CHO group or a moiety having the formula:
55
provided that at least one of A is not -CHO; and
Y is a hydroxy group, an alkoxy group, or an alkanoyloxy group.

### Claim 33

A method of producing a betulinol-antibody conjugate having the formula:
56
wherein
A are independently selected from a —CHO group or a moiety having the formula:
57
provided that at least one of A is not -CHO; and
Y is a hydroxy group, an alkoxy group, or an alkanoyloxy group,
said method comprising:
providing a carrier molecule having the formula:
58
and
converting the carrier molecule with a hydrazide having the formula:
59
and an antibody having the formula H-antibody-OH under conditions effective to produce the betulinol-antibody conjugate.

### Claim 34 (depends on 33)

A method according to claim 33, wherein said converting the carrier molecule comprises:
reacting the carrier molecule with the antibody under conditions effective to produce an antibody-bound carrier molecule having the formula:
60
and
converting the antibody-bound carrier molecule with the hydrazide under conditions effective to produce the betulinol-antibody conjugate.

### Claim 35 (depends on 33)

A method according to claim 33, wherein said converting the carrier molecule comprises:
reacting the carrier molecule with the hydrazide under conditions effective to produce a betulinol-bound carrier molecule having the formula:
61
wherein
at least one A is a moiety having the formula:
62
and
converting the betulinol-bound carrier molecule with the antibody under conditions effective to produce the betulinol-antibody conjugate.

### Claim 36

A betulinol-antibody conjugate having the formula:
HO-antibody-spacer-(A)n
wherein
A is a moiety having the formula:
63
Y is a hydroxy group, an alkoxy group, or an alkanoyloxy group; and
n is an integer from 1 to 100.

### Claim 37 (depends on 36)

A betulinol-antibody conjugate according to claim 36, wherein -spacer-(A)n has the formula:
64
wherein
a is an integer from 1 to 100 and
b is an integer equal to n.

### Claim 38 (depends on 36)

A betulinol-antibody conjugate according to claim 36, wherein spacer is a diamine derivative of polyethylene glycol having 2-(pyridyldithio)-propionyl and N-hydroxysuccinimide ester groups bonded thereto.

### Claim 39 (depends on 36)

A betulinol-antibody conjugate according to claim 36, wherein spacer is a branched form of polyethylene glycol propionic acid N-hydroxysuccinimide ester.

### Claim 40 (depends on 39)

A betulinol-antibody conjugate according to claim 39, wherein the branched form of polyethylene glycol propionic acid N-hydroxysuccinimide ester is a monomethoxypoly(ethylene glycol)-propionic acid N-hydroxysuccinimide ester.

### Claim 41

A method of producing a betulinol-antibody conjugate having the formula:
HO-antibody-spacer-(A)n
wherein
A is a moiety having the formula:
65
Y is a hydroxy group, an alkoxy group, or an alkanoyloxy group; and
n is an integer from 1 to 100,
said method comprising:
providing a crosslinker having a first reactive terminus and one or more second reactive termini;
reacting an antibody with the first reactive terminus; and
reacting a hydrazide having the formula:
66
with one or more of the one or more second reactive termini under conditions effective to produce the betulinol-antibody conjugate.

### Claim 42 (depends on 41)

A method according to claim 41, wherein the first reactive terminus is selected from the group consisting of a hydroxy group, an aldehyde group, and a carboxyl group.

### Claim 43 (depends on 41)

A method according to claim 41, wherein each of the one or more second reactive termini are independently selected from the group consisting of a hydroxy group, an aldehyde group, and a carboxyl group.

### Claim 44 (depends on 41)

A method according to claim 41, wherein -spacer-(A)n has the formula:
67
wherein
a is an integer from 1 to 100 and
b is an integer equal to n.

### Claim 45 (depends on 41)

A method according to claim 41, wherein spacer is a diamine derivative of polyethylene glycol having 2-(pyridyldithio)-propionyl and N-hydroxysuccinimide ester groups bonded thereto.

### Claim 46 (depends on 41)

A method according to claim 41, wherein spacer is a branched form of polyethylene glycol propionic acid N-hydroxysuccinimide ester.

### Claim 47 (depends on 46)

A method according to claim 46, wherein the branched form of polyethylene glycol propionic acid N-hydroxysuccinimide ester is a monomethoxypoly(ethylene glycol)-propionic acid N-hydroxysuccinimide ester.

### Claim 48

A method of treating cancer comprising:
administering to a cancer patient an effective amount of a compound selected from the group consisting of betulonic aldehyde and compounds having the formulae:
68
and
HO-antibody-spacer-(A2)n
wherein
A1 is a moiety having the formula:
69
A2 is a moiety having the formula:
70
n is an integer from 1 to 100;
X and Y1 are each independently selected from the group consisting of a hydroxy group, an alkoxy group, an alkanoyloxy group, and a -peptide-NHNH-C(O)-antibody-OH moiety;
Y2 is selected from the group consisting of a hydroxy group, an alkoxy group, and an alkanoyloxy group; and
HO-antibody-H is an antibody targeted to a site to be treated in the patient.

### Claim 49 (depends on 48)

A method according to claim 48, wherein the compound is betulinol diacetate.

### Claim 50 (depends on 48)

A method according to claim 48, wherein the compound is betulonic aldehyde.

### Claim 51 (depends on 50)

A method according to claim 50, wherein the compound is betulinol dimethyl diether.
